232 related articles for article (PubMed ID: 14760122)
1. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial.
Sieber M; Tesch H; Pfistner B; Rueffer U; Paulus U; Munker R; Hermann R; Doelken G; Koch P; Oertel J; Roller S; Worst P; Bischof H; Glunz A; Greil R; von Kalle K; Schalk KP; Hasenclever D; Brosteanu O; Duehmke E; Georgii A; Engert A; Loeffler M; Diehl V; Mueller RP; Willich N; Fischer R; Hansmann ML; Stein H; Schober T; Koch B;
Ann Oncol; 2004 Feb; 15(2):276-82. PubMed ID: 14760122
[TBL] [Abstract][Full Text] [Related]
2. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
3. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
4. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
5. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
7. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).
Diehl V; Loeffler M; Pfreundschuh M; Ruehl U; Hasenclever D; Nisters-Backes H; Sieber M; Smith K; Tesch H; Geilen W
Ann Oncol; 1995 Nov; 6(9):901-10. PubMed ID: 8624293
[TBL] [Abstract][Full Text] [Related]
8. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group.
Diehl V; Pfreundschuh M; Löffler M; Rühl U; Hiller E; Gerhartz H; Wilmanns W; Kirchner H; Schoppe W; Petsch S
Med Oncol Tumor Pharmacother; 1989; 6(2):155-62. PubMed ID: 2473363
[TBL] [Abstract][Full Text] [Related]
10. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
11. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
12. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).
Ballova V; Rüffer JU; Haverkamp H; Pfistner B; Müller-Hermelink HK; Dühmke E; Worst P; Wilhelmy M; Naumann R; Hentrich M; Eich HT; Josting A; Löffler M; Diehl V; Engert A
Ann Oncol; 2005 Jan; 16(1):124-31. PubMed ID: 15598949
[TBL] [Abstract][Full Text] [Related]
13. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.
Tesch H; Diehl V; Lathan B; Hasenclever D; Sieber M; Rüffer U; Engert A; Franklin J; Pfreundschuh M; Schalk KP; Schwieder G; Wulf G; Dölken G; Worst P; Koch P; Schmitz N; Bruntsch U; Tirier C; Müller U; Loeffler M
Blood; 1998 Dec; 92(12):4560-7. PubMed ID: 9845521
[TBL] [Abstract][Full Text] [Related]
14. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.
Diehl V; Sieber M; Rüffer U; Lathan B; Hasenclever D; Pfreundschuh M; Loeffler M; Lieberz D; Koch P; Adler M; Tesch H
Ann Oncol; 1997 Feb; 8(2):143-8. PubMed ID: 9093722
[TBL] [Abstract][Full Text] [Related]
15. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
16. Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua.
Baez F; Ocampo E; Conter V; Flores A; Gutierrez T; Malta A; Pacheco C; Palacios R; Biondi A; Riva L; Sala A; Silvestri D; Cavalli F; Sessa C; Casanova M; Masera G
Ann Oncol; 1997 Mar; 8(3):247-50. PubMed ID: 9137793
[TBL] [Abstract][Full Text] [Related]
17. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
18. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
19. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
[TBL] [Abstract][Full Text] [Related]
20. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.
Skoetz N; Trelle S; Rancea M; Haverkamp H; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2013 Sep; 14(10):943-52. PubMed ID: 23948348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
